- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Will Germany's Cannabis Actions Create a Domino Effect in Europe?
Experts think recreational cannabis legalization in Germany could pressure nearby countries to follow suit.
As Germany gears up to possibly legalize adult-use cannabis, how likely is it that the country's plans will cause other nations in Europe to follow suit?
The roadmap for recreational cannabis legalization in Germany has become a hot topic for stakeholders in the overall industry. On top of how exactly the situation will play out and what business opportunities exist, market watchers have offered various opinions on what the lasting impact of this change could be.
Can legalization cause cannabis FOMO?
Experts on the US cannabis market have seen a clear knock-on effect in the US — when one state market opens its doors, nearby states tend to reconsider their cannabis plans.
For example, New Jersey kicked off its adult-use program this year, and Kacey Morrissey, senior director of industry analytics with New Frontier Data, told the Investing News Network (INN) this change would “create a lot of additional pressure” for neighboring states such as New York and Pennsylvania.
If this happens in US states, could legalization in Germany have the same impact in Europe?
Shane MacGuill, global lead of nicotine and cannabis with Euromonitor International, told INN that the road ahead for German legalization won’t be easy, but if it gets done, he expects to see changes throughout Europe.
“I think there's lots of obstacles before Germany legalizes,” he said. “I don't want to make it sound like it's a (done deal), but if and when that happens, you're going to see that countries will have no choice but to probably try and regulate themselves.”
The analyst pointed to Portugal as another European nation that could pressure nearby countries to adapt. The country currently has a medical cannabis program in place, and is discussing a new policy to regulate personal use. MacGuill said legalization in Portugal would pressure Spain to move forward with its own plans.
“That's a very key element of it in Europe,” MacGuill said. “In a broader sense, legalization is always pragmatic.”
Bethany Gomez, managing director at the Brightfield Group, told INN the cannabis industry has been marked by incremental shifts when it comes to policy.
The analyst said she expects to see the same in Germany when it comes to cannabis regulation. “There's still a lot of hedging that is being done (by governments) on whether this is an experiment, whether they want to go all in planting their flag in it. It'll certainly require a lot of political will to make that shift,” Gomez told INN.
German market attracting cannabis stakeholders
Germany is targeting a speedy process for the opening of its adult-use market; this has caused some experts to express caution to those interested in the European nation.
“2023 is when (the Germans) intend to have products being sold by, which in my opinion, given where they're at today, is an extremely ambitious plan,” Deepak Anand, founder of medical cannabis firm Materia, said during a panel at the recent Lift Expo, held in Toronto.
At the same panel, Terry Booth, CEO of Australis Capital (CSE:AUSA,OTCQB:AUSAF) and former CEO of Aurora Cannabis (NASDAQ:ACB,TSX:ACB), said he expects Germany to over-regulate and “be tougher than Canada.”
MacGuill told INN that Germany’s adult-use intentions wouldn't have come to light without Canada becoming the first G7 country to legalize the drug. “Legalization (in Canada) is certainly something that people are aware of in Europe, and has had an influence on it,” he explained.
Investor takeaway
As more nations globally open their doors to cannabis programs, there's potential for a domino effect to accelerate the availability of cannabis across the world.
However, it will be critical for investors to practice patience, as many experts have advised, because changes are not seen from one day to the next when it comes to cannabis policy.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.